Tenax Therapeutics Inc Quick Ratio (TENX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Tenax Therapeutics Inc   (NASDAQ: TENX)

Tenax Therapeutics Inc 's Quick Ratio

TENX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Tenax Therapeutics Inc 's Cash & cash equivalent grew by % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Tenax Therapeutics Inc 's Quick Ratio to 14.62, above Tenax Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Quick Ratio than Tenax Therapeutics Inc in second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents TENX´s has?
What are TENX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TENX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 219.47 % 206.58 % 52.48 % 157.6 % 45.16 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 14.62 - - - -
TENX's Total Ranking # # # # #
Seq. Current Liabilities Change -4.87 % 18.59 % 8.44 % 161.14 % -8.71 %
Seq. Cash & cash equivalent Change - - - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 74
Healthcare Sector # 108
Overall Market # 328


Quick Ratio Statistics
High Average Low
36.09 6.51 0.41
(Jan 31 2015)   (Jan 31 2014)




Financial Statements
Tenax Therapeutics Inc 's Current Liabilities $ 8 Millions Visit TENX's Balance sheet
Tenax Therapeutics Inc 's Cash & cash equivalent $ 118 Millions Visit TENX's Balance sheet
Source of TENX's Sales Visit TENX's Sales by Geography


Cumulative Tenax Therapeutics Inc 's Quick Ratio

TENX's Quick Ratio for the trailling 12 Months

TENX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 141.55 % 110.55 % 72.77 % 67.21 % 57.66 %
Y / Y Cash & cash equivalent TTM Growth - - - - -
Quick Ratio TTM 3.89 - - - -
Total Ranking TTM #
Seq. Current Liabilities TTM Growth 22.39 % 30.02 % 14.85 % 32.17 % 6.68 %
Seq. Cash & cash equivalent TTM Growth - - - - -

Quick ratio ranking by company, industry and sector >> Back to TENX Financial Strength Comparisons >> Go to Compare TENX Quick Ratio to its Competitors

On the trailing twelve months basis TENX Cash & cash equivalent remained unchanged by % in Q2 2026 year on year, faster than Current Liabilities, this led to